

# Wilson I Gonsalves

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/904912/wilson-i-gonsalves-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

370 papers	3,497 citations	30 h-index	48 g-index
400 ext. papers	4,603 ext. citations	3.9 avg, IF	5.01 L-index

#	Paper	IF	Citations
370	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.. <i>Leukemia</i> , <b>2022</b> ,	10.7	2
369	Melflufen for multiple myeloma: a promise unfulfilled?. <i>Lancet Haematology,the</i> , <b>2022</b> ,	14.6	2
368	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.. <i>Bone Marrow Transplantation</i> , <b>2022</b> ,	4.4	
367	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 59	7	0
366	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.. <i>Leukemia and Lymphoma</i> , <b>2022</b> , 1-6	1.9	0
365	Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing.. <i>Annals of Pharmacotherapy</i> , <b>2022</b> , 10600280221087218	2.9	
364	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.. <i>JCO Oncology Practice</i> , <b>2022</b> , OP2100789	2.3	
363	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. <i>Blood</i> , <b>2021</b> , 138, 1639-1639	2.2	2
362	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , <b>2021</b> , 138, 2707-2707	2.2	
361	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFNENIS). <i>Blood</i> , <b>2021</b> , 138, 1333-1333	2.2	
360	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , <b>2021</b> , 138, 2700-2700	2.2	
359	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio $\geq 100$ . <i>Blood</i> , <b>2021</b> , 138, 1617-1617	2.2	
358	Disrupting the Reverse Warburg Effect As a Therapeutic Strategy in Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 2649-2649	2.2	
357	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. <i>Blood</i> , <b>2021</b> , 138, 819-819	2.2	
356	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. <i>Blood</i> , <b>2021</b> , 138, 3805-3805	2.2	
355	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 186	7	1
354	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 3760-3760	2.2	0

353	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. <i>Blood</i> , <b>2021</b> , 138, 3773-3773	2.2	
352	Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 2711-2711	2.2	0
351	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. <i>Blood</i> , <b>2021</b> , 138, 3761-3761	2.2	
350	Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , <b>2021</b> ,	7.1	1
349	Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 2735-2735	2.2	1
348	Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , <b>2021</b> , 138, 3774-3774	2.2	0
347	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 1619-1619	2.2	
346	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. <i>Blood</i> , <b>2021</b> , 138, 543-543	2.2	
345	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. <i>Blood</i> , <b>2021</b> , 138, 1630-1630	2.2	
344	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , <b>2021</b> , 138, 119-119	2.2	
343	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 2650-2650	2.2	
342	Single Cell Transcriptome Profile of Myeloma and Immune Cell Characteristics in Patients with Durable Response Post CART. <i>Blood</i> , <b>2021</b> , 138, 3838-3838	2.2	1
341	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 192	7	10
340	Supportive care in multiple myeloma: Current practices and advances. <i>Cancer Treatment and Research Communications</i> , <b>2021</b> , 29, 100476	2	
339	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , <b>2021</b> ,	10.7	5
338	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. <i>Leukemia</i> , <b>2021</b> ,	10.7	1
337	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 677-687	6.4	4
336	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 50	7	8

335	Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, 355-360	2	0
334	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e20076-e20016		
333	Chemotherapy-based stem cell mobilization in multiple myeloma patients treated with novel agents: The Mayo Clinic experience.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e20000-e20000	2.2	1
332	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 945-953	7.1	2
331	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 1546-1577	6.4	8
330	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, 451-460.e2	2	2
329	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 589.e1-589.e6		2
328	Enzymatic activation of pyruvate kinase increases cytosolic oxaloacetate to inhibit the Warburg effect. <i>Nature Metabolism</i> , <b>2021</b> , 3, 954-968	14.6	4
327	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. <i>Blood Advances</i> , <b>2021</b> , 5, 2753-2759	7.8	0
326	Ageism in the t(11;14) Subtype of Multiple Myeloma. <i>Acta Haematologica</i> , <b>2021</b> , 144, 6-7	2.7	0
325	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 274-277	4.4	0
324	Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E35-E38	7.1	0
323	Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 354-361	3.8	3
322	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 433-436	3.8	0
321	Autologous stem cell transplantation for multiple myeloma patients aged ≥75 treated with novel agents. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1144-1150	4.4	5
320	Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 380-385	4.5	9
319	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 330-337	7.1	3
318	Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 67-70	4.9	10

317	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 928-935	4.4	2
316	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 309.e1-309.e5		
315	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 316-322	1.9	1
314	Amyloid arthropathy in smoldering myeloma: Do not take it lightly. <i>Leukemia Research Reports</i> , <b>2021</b> , 15, 100242	0.6	0
313	Practical management and assessment of primary plasma cell leukemia in the novel agent era. <i>Cancer Treatment and Research Communications</i> , <b>2021</b> , 28, 100414	2	
312	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , <b>2021</b> , 35, 1428-1437	10.7	4
311	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E157-E162	7.1	2
310	Prognostic restaging after treatment initiation in patients with AL amyloidosis. <i>Blood Advances</i> , <b>2021</b> , 5, 1029-1036	7.8	3
309	Coagulation Abnormalities in Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 377-387	6.4	3
308	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 3011-3018	1.9	0
307	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 1131-1136	7.1	6
306	Disease outcomes and biomarkers of progression in smoldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2021</b> , 195, 210-216	4.5	5
305	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 770.e1-770.e7		0
304	Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma. <i>Cancer Treatment and Research Communications</i> , <b>2021</b> , 29, 100444	2	1
303	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 446-454	7.1	3
302	In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells. <i>Cancer &amp; Metabolism</i> , <b>2020</b> , 8, 29	5.4	6
301	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 124	7	1
300	Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. <i>Blood Advances</i> , <b>2020</b> , 4, 5425-5430	7.8	10

299	Reductive amination of Ketoglutarate in metabolite extracts results in glutamate overestimation. <i>Journal of Chromatography A</i> , <b>2020</b> , 1623, 461169	4.5	2
298	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 2132-2137	4.4	5
297	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1402-1405	4.7	2
296	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 52	7	4
295	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 55	7	22
294	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1297-1304	4.4	3
293	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a 'graft versus host'-like syndrome and poor outcomes. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1879-1881	4.4	1
292	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 637-642	7.1	6
291	Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma. <i>Scientific Reports</i> , <b>2020</b> , 10, 10250	4.9	7
290	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 20	7	18
289	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 4	7	12
288	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 497-502	7.1	27
287	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, 596-601	2	3
286	Of lions, shar-pei, and doughnuts: a tale retold. <i>Blood</i> , <b>2020</b> , 135, 1074-1076	2.2	2
285	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 27-28	2.2	
284	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. <i>Blood</i> , <b>2020</b> , 136, 44-45	2.2	
283	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 15-16	2.2	
282	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. <i>Blood</i> , <b>2020</b> , 136, 14-15	2.2	

281	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. <i>Blood</i> , <b>2020</b> , 136, 6-7	2.2	
280	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , <b>2020</b> , 136, 21-22	2.2	
279	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , <b>2020</b> , 136, 21-22	2.2	
278	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥75 Treated with Novel Agents. <i>Blood</i> , <b>2020</b> , 136, 12-13	2.2	
277	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. <i>Blood</i> , <b>2020</b> , 136, 31-32	2.2	0
276	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. <i>Blood</i> , <b>2020</b> , 136, 37-38	2.2	
275	Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL). <i>Blood</i> , <b>2020</b> , 136, 29-30	2.2	1
274	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , <b>2020</b> , 136, 41-42	2.2	
273	Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes. <i>Blood</i> , <b>2020</b> , 136, 44-45	2.2	
272	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. <i>Blood</i> , <b>2020</b> , 136, 52-53	2.2	2
271	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , <b>2020</b> , 136, 48-49	2.2	0
270	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 36-37	2.2	3
269	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , <b>2020</b> , 136, 30-31	2.2	2
268	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , <b>2020</b> , 136, 7-8	2.2	1
267	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). <i>Blood</i> , <b>2020</b> , 136, 12-13	2.2	2
266	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. <i>Blood</i> , <b>2020</b> , 136, 22-23	2.2	1
265	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. <i>Blood Advances</i> , <b>2020</b> , 4, 2236-2244	7.8	7
264	Characteristics and outcome of patients with MYD88 wild-type Waldenström Macroglobulinemia.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8550-8550	2.2	2



263	Prognostic role of beta-2 microglobulin in patients with light chain amyloidosis treated with autologous stem cell transplantation.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e20506-e20506	2.2	
262	Outcomes of patients with primary plasma cell leukemia (pPCL) in the era of novel agent therapy.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e20510-e20510	2.2	1
261	Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8516-8516	2.2	
260	Quality of life (QOL), financial burden, and perception of care in patients enrolled on clinical trials (CTs).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e19112-e19112	2.2	1
259	Assessing the utility of monitoring IgA multiple myeloma patients with quantitative serum IgA levels.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e20515-e20515	2.2	
258	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , <b>2020</b> , 188, 394-403	4.5	23
257	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E8-E10	7.1	5
256	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 4-9	7.1	6
255	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, 53-56	2	5
254	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 310-315	7.1	16
253	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E60-E62	7.1	1
252	Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 274-281	7.1	18
251	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , <b>2020</b> , 34, 1373-1382	10.7	22
250	Revisiting complete response in light chain amyloidosis. <i>Leukemia</i> , <b>2020</b> , 34, 1472-1475	10.7	10
249	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , <b>2020</b> , 34, 1135-1143	10.7	19
248	Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. <i>Cancer Medicine</i> , <b>2020</b> , 9, 8895-8901	4.8	1
247	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 2975-2979	1.9	1
246	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 1280-1287	7.1	10



245	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2020</b> , 27, 13-16	2.7	21
244	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , <b>2020</b> , 34, 3338-3347	10.7	15
243	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. <i>Blood Advances</i> , <b>2020</b> , 4, 322-326	7.8	4
242	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , <b>2019</b> , 33, 811-814	10.7	15
241	Crystalglobulin-Induced Nephropathy and Keratopathy. <i>Kidney Medicine</i> , <b>2019</b> , 1, 71-74	2.8	4
240	Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1898-1907	4.4	0
239	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 2039-2050	4.4	6
238	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2960-2967	1.9	2
237	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1520-1525	4.7	6
236	Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 701-707	4.5	10
235	Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma. <i>Haematologica</i> , <b>2019</b> , 104, 2061-2074	6.6	22
234	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 32	7	22
233	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1775-1779	4.4	5
232	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 751-756	7.1	6
231	Substratification of patients with newly diagnosed standard-risk multiple myeloma. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 254-260	4.5	8
230	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , <b>2019</b> , 33, 1268-1272	10.7	4
229	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 587-594	4.4	7
228	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 442-447	4.4	5

227	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 353-367	4.4	51
226	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , <b>2019</b> , 187, 588-594	4.5	26
225	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2019</b> , 26, 101-102	2.7	4
224	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. <i>Blood Advances</i> , <b>2019</b> , 3, 1226-1229	7.8	3
223	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. <i>Cancer</i> , <b>2019</b> , 125, 3574-3581	6.4	3
222	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 1020-1026	7.1	25
221	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 1066-1071	7.1	9
220	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , <b>2019</b> , 134, 4334-4334	2.2	1
219	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 4386-4386	2.2	2
218	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 864-864	2.2	12
217	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 1905-1905	2.2	1
216	Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 7509-7509	2.2	4
215	Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 7559-7559	2.2	6
214	Ixazomib, lenalidomide, and dexamethasone for patients with POEMS syndrome.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 8019-8019	2.2	1
213	Continued improvement in survival in multiple myeloma (MM) including high-risk patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 8039-8039	2.2	22
212	Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e19519-e19519	2.2	2
211	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , <b>2019</b> , 94, 455-464	6.4	13
210	Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with three or more organs involved.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 8011-8011	2.2	

209	Upstaging the R-ISS classification of newly diagnosed multiple myeloma (NDMM) patients (pts) by quantifying circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 8031-8031	2.2	1
208	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 8034-8034	2.2	
207	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 4505-4505	2.2	
206	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). <i>Blood</i> , <b>2019</b> , 134, 5523-5523	2.2	
205	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , <b>2019</b> , 134, 1532-1532	2.2	
204	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 4396-4396	2.2	
203	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. <i>Blood</i> , <b>2019</b> , 134, 3080-3080	2.2	
202	Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 3160-3160	2.2	1
201	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 5833-5833	2.2	
200	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 1904-1904	2.2	
199	Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. <i>Blood</i> , <b>2019</b> , 134, 1697-1697	2.2	
198	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , <b>2019</b> , 134, 5532-5532	2.2	
197	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. <i>Blood</i> , <b>2019</b> , 134, 3171-3171	2.2	0
196	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 2197-2197	2.2	
195	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , <b>2019</b> , 134, 5490-5490	2.2	1
194	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E141-E143	7.1	13
193	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , <b>2019</b> , 33, 1273-1277	10.7	7
192	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , <b>2019</b> , 94, 472-483	6.4	33

191	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , <b>2019</b> , 3, 1930-1938	7.8	20
190	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , <b>2019</b> , 3, 744-750	7.8	15
189	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. <i>Leukemia Research</i> , <b>2019</b> , 87, 106264	2.7	
188	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 424-430	7.1	5
187	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, e108-e111	4.7	11
186	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1077-1081	4.4	3
185	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , <b>2019</b> , 33, 790-794	10.7	16
184	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , <b>2019</b> , 33, 730-738	10.7	11
183	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , <b>2019</b> , 33, 527-531	10.7	30
182	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , <b>2019</b> , 33, 531-536	10.7	60
181	Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 1014-1017	4.5	11
180	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 306-311	7.1	9
179	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , <b>2018</b> , 32, 1421-1426	10.7	5
178	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , <b>2018</b> , 32, 2240-2249	10.7	49
177	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , <b>2018</b> , 103, 1229-1234	6.6	8
176	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 889-894	7.1	8
175	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2127-2132	4.7	12
174	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , <b>2018</b> , 97, 1417-1425	3	43

173	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. <i>Leukemia</i> , <b>2018</b> , 32, 1414-1420	10.7	9
172	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , <b>2018</b> , 32, 1811-1815	10.7	18
171	Carnitine Palmitoyltransferase 1A Has a Lysine Succinyltransferase Activity. <i>Cell Reports</i> , <b>2018</b> , 22, 1365-1373	10.7	36
170	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 326-333	4.4	4
169	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , <b>2018</b> , 93, 56-58	6.4	12
168	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 71-77	4.5	9
167	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 179-186	7.1	29
166	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 187-194	7.1	45
165	Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). <i>European Journal of Haematology</i> , <b>2018</b> , 100, 215-217	3.8	40
164	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , <b>2018</b> , 93, 17-22	7.1	9
163	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2157-2159	4.7	3
162	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 70	7	11
161	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1207-1210	7.1	1
160	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1384-1393	7.1	15
159	59-Year-Old Man With Fatigue, Weight Loss, and Hepatomegaly. <i>Mayo Clinic Proceedings</i> , <b>2018</b> , 93, 1525-1529	10.7	1
158	Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2018</b> , 13, 1037-1046	6.9	32
157	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 59	7	115
156	Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	23

155	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 304-304	2.2	8
154	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. <i>Blood</i> , <b>2018</b> , 132, 4460-4460	2.2	0
153	Daratumumab-based therapies in patients with AL amyloidosis.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8053-8053	2.2	2
152	Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. <i>Oncotarget</i> , <b>2018</b> , 9, 34582-34594	3.3	3
151	Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8023-8023	2.2	
150	Natural history of del53 multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e20017-e20017	2.2	
149	Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8045-8045	2.2	
148	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8030-8030	2.2	
147	Long-Term Survivorship with Active Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 1912-1912	2.2	
146	Comparative Analysis of Staging Systems in AL Amyloidosis. <i>Blood</i> , <b>2018</b> , 132, 3228-3228	2.2	
145	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 3159-3159		
144	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 3158-3158	2.2	
143	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 4449-4449	2.2	
142	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. <i>Blood</i> , <b>2018</b> , 132, 2147-2147	2.2	
141	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. <i>Blood</i> , <b>2018</b> , 132, 3226-3226		
140	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. <i>Blood</i> , <b>2018</b> , 132, 1606-1606	2.2	1
139	Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. <i>Blood</i> , <b>2018</b> , 132, 4613-4613	2.2	
138	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 4497-4497	2.2	



137	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). <i>Blood</i> , <b>2018</b> , 132, 4502-4502	2.2	
136	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 1902-1902	2.2	
135	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. <i>Blood</i> , <b>2018</b> , 132, 5594-5594	2.2	
134	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. <i>Blood</i> , <b>2018</b> , 132, 3227-3227	2.2	
133	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. <i>Blood</i> , <b>2018</b> , 132, 5610-5610	2.2	
132	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , <b>2018</b> , 132, 3268-3268	2.2	
131	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. <i>Blood</i> , <b>2018</b> , 132, 3436-3436	2.2	
130	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2018</b> , 132, 2884-2884	2.2	1
129	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 4615-4615	2.2	
128	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 3160-3160	2.2	2
127	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. <i>Blood</i> , <b>2018</b> , 132, 4152-4152		1
126	Patient-Reported Outcome Driven Case Management System for Hematology In Prospective Study. <i>Blood</i> , <b>2018</b> , 132, 719-719	2.2	
125	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1323-1329	2.2	68
124	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 106	7	13
123	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 116	7	38
122	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 125	7	17
121	Utility and prognostic value of F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1518-1523	7.1	15
120	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , <b>2018</b> , 2, 769-776	7.8	16

119	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. <i>Blood Advances</i> , <b>2018</b> , 2, 3149-3154	7.8	17
118	Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?. <i>American Journal of Clinical Pathology</i> , <b>2018</b> , 150, 168-176	1.9	4
117	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2360-2364	4.7	13
116	Estimating the annual volume of hematologic cancer cases per hematologist-oncologist in the United States: are we treating rare cancers too rarely?. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 251-252	1.9	3
115	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , <b>2017</b> , 49, 545-551	1.5	27
114	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 435-440	7.1	10
113	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. <i>Blood</i> , <b>2017</b> , 129, 82-87	2.2	41
112	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , <b>2017</b> , 129, 2111-2119	2.2	181
111	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2017</b> , 24, 40-41	2.7	3
110	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , <b>2017</b> , 92, E507-E512	7.1	3
109	Sex-based disparities in venous thromboembolism outcomes: A National Inpatient Sample (NIS)-based analysis. <i>Vascular Medicine</i> , <b>2017</b> , 22, 121-127	3.3	9
108	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 668-673	7.1	46
107	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. <i>Mayo Clinic Proceedings</i> , <b>2017</b> , 92, 578-598	6.4	88
106	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 549-554	7.1	18
105	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1257-1265	13.4	82
104	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. <i>Mayo Clinic Proceedings</i> , <b>2017</b> , 92, 908-917	6.4	43
103	Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. <i>Blood</i> , <b>2017</b> , 130, 1578-1584	2.2	15
102	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 888-895	4.5	14

101	POEMS syndrome: An elusive diagnosis. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 1269-1270	7.1	1
100	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 98-105	4.5	12
99	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 1146-1155	7.1	22
98	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2017</b> , 24, 183-188	2.7	1
97	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , <b>2017</b> , 130, 1198-1204	2.2	46
96	The next generation of novel therapies for the management of relapsed multiple myeloma. <i>Future Oncology</i> , <b>2017</b> , 13, 63-75	3.6	7
95	Natural history of amyloidosis isolated to fat and bone marrow aspirate. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 170-172	4.5	7
94	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 50-55	7.1	30
93	What are patients' biggest concerns? A patient reported outcome case-management system.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 6572-6572	2.2	2
92	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8038-8038	2.2	1
91	Factors predicting organ response in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8048-8048	2.2	1
90	Natural history of t(11;14) multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8014-8014	2.2	0
89	The use of proteasome inhibitors among patients with POEMS syndrome.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e19530-e19530	2.2	
88	Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8049-8049	2.2	
87	Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8047-8047	2.2	
86	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e19532-e19532	2.2	
85	Smoldering Waldenström's macroglobulinemia (SWM): Analysis from the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1573-1573	2.2	
84	The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8032-8032	2.2	

83	Treatment approaches and outcomes in extramedullary plasmacytomas.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8050-8050	2.2	
82	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 1129-1134	7.1	42
81	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations. <i>American Journal of Clinical Pathology</i> , <b>2016</b> , 145, 843-51	1.9	33
80	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, 1284-9	4.3	21
79	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , <b>2016</b> , 128, 2082-2082	2.2	1
78	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , <b>2016</b> , 128, 2968-2968	2.2	3
77	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2016</b> , 128, 2972-2972	2.2	2
76	Clinical Features and Outcomes of Plasmacytoma in the United States: Analysis Using the National Cancer Data Base. <i>Blood</i> , <b>2016</b> , 128, 3249-3249	2.2	1
75	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. <i>Blood</i> , <b>2016</b> , 128, 3272-3272	2.2	1
74	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. <i>Blood</i> , <b>2016</b> , 128, 3317-3317	2.2	3
73	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , <b>2016</b> , 128, 3337-3337	2.2	5
72	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , <b>2016</b> , 128, 3444-3444	2.2	1
71	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , <b>2016</b> , 128, 4627-4627	2.2	1
70	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 8004-8004	2.2	1
69	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 8015-8015	2.2	1
68	Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 8035-8035	2.2	
67	Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 8053-8053	2.2	
66	Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 8017-8017	2.2	

65	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7552-7552	2.2	1
64	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 8062-8062	2.2	
63	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 8016-8016	2.2	
62	Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2016</b> , 128, 2960-2960	2.2	
61	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 5615-5615	2.2	
60	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. <i>Blood</i> , <b>2016</b> , 128, 3273-3273	2.2	
59	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. <i>Blood</i> , <b>2016</b> , 128, 3251-3251	2.2	
58	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , <b>2016</b> , 128, 1810-1810	2.2	
57	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. <i>Blood</i> , <b>2016</b> , 128, 3306-3306	2.2	
56	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 1194-1194	2.2	
55	Sex-Based Disparities in Venous Thromboembolism Sociodemographics and Outcomes: A National Inpatient Sample (NIS)-Based Analysis. <i>Blood</i> , <b>2016</b> , 128, 5918-5918	2.2	0
54	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. <i>Blood</i> , <b>2016</b> , 128, 3269-3269	2.2	
53	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , <b>2016</b> , 128, 3338-3338	2.2	
52	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. <i>Blood</i> , <b>2016</b> , 128, 3255-3255	2.2	
51	Outcome of Very Young (<40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , <b>2016</b> , 128, 5576-5576	2.2	
50	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. <i>Blood</i> , <b>2016</b> , 128, 2187-2187	2.2	
49	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 2267-2267	2.2	
48	Effect of Surgical Intervention on Survival of Patients With Clinical N2 Non-Small Cell Lung Cancer: A Veterans' Affairs Central Cancer Registry (VACCR) Database Analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2016</b> , 39, 142-6	2.7	3



47	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 984-8	7.1	37
46	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. <i>Leukemia Research</i> , <b>2016</b> , 44, 32-9	2.7	13
45	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2016</b> , 16, 447-52	2	19
44	Myelomatous Involvement of the Central Nervous System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2016</b> , 16, 644-654	2	29
43	Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , <b>2016</b> , 91, 1354-1361	6.4	30
42	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 1123-1128	7.1	52
41	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 585-9	7.1	40
40	Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 101-8	7.1	16
39	The use of novel agents in multiple myeloma patients with hepatic impairment. <i>Future Oncology</i> , <b>2015</b> , 11, 501-10	3.6	11
38	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. <i>Blood</i> , <b>2015</b> , 126, 1830-1830	2.2	1
37	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , <b>2015</b> , 126, 4197-4197	2.2	5
36	Estimating the Annual Volume of Hematologic Cancer Cases per Hematologist-Oncologist in the United States: Are We Treating Rare Cancers Too Rarely?. <i>Blood</i> , <b>2015</b> , 126, 3297-3297	2.2	
35	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 4176-4176	2.2	
34	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. <i>Blood</i> , <b>2015</b> , 126, 5303-5303	2.2	
33	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. <i>Blood</i> , <b>2015</b> , 126, 4370-4370	2.2	
32	Drugs that affect blood coagulation, fibrinolysis, and hemostasis. <i>Side Effects of Drugs Annual</i> , <b>2014</b> , 35, 617-631	0.2	
31	Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	109
30	Quantification of clonal circulating plasma cells in relapsed multiple myeloma. <i>British Journal of Haematology</i> , <b>2014</b> , 167, 500-5	4.5	62



29	Sarcoidosis presenting with pancytopenia. <i>American Journal of Medicine</i> , <b>2014</b> , 127, e9-10	2.4	20
28	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. <i>Blood</i> , <b>2014</b> , 124, 907-12	2.2	83
27	Bortezomib-based combination regimens in myeloma: more is not necessarily better. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 1439-40	1.9	
26	Prognostic Significance of Quantifying Circulating Plasma Cells in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2014</b> , 14, S147	2	6
25	Epstein-barr virus infection in an elderly nonimmunocompromised adult successfully treated with rituximab. <i>Case Reports in Hematology</i> , <b>2014</b> , 2014, 641483	0.7	2
24	Secondary Hemophagocytic Syndrome Associated with Richter's Transformation in Chronic Lymphocytic Leukemia. <i>Case Reports in Hematology</i> , <b>2014</b> , 2014, 287479	0.7	
23	Association between race and survival of patients with non--small-cell lung cancer in the United States veterans affairs population. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 152-8	4.9	28
22	Early Mortality in Multiple Myeloma: Risk Factors and Impact on Population Outcomes. <i>Blood</i> , <b>2014</b> , 124, 1320-1320	2.2	4
21	Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). <i>Blood</i> , <b>2014</b> , 124, 304-304	2.2	24
20	PET-CT Has Major Diagnostic Value in the Evaluation of Smoldering Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 3382-3382	2.2	3
19	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses. <i>Blood</i> , <b>2014</b> , 124, 4780-4780	2.2	
18	Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients. <i>Blood</i> , <b>2014</b> , 124, 4751-4751	2.2	
17	Improvement in Renal Function and Its Impact on Survival in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 3368-3368	2.2	
16	Gallbladder cancer-associated thrombotic microangiopathy. <i>Future Oncology</i> , <b>2013</b> , 9, 1711-5	3.6	1
15	The new oral anticoagulants in clinical practice. <i>Mayo Clinic Proceedings</i> , <b>2013</b> , 88, 495-511	6.4	79
14	Visual loss in early-stage chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e280-2	2.2	8
13	Chronic Eosinophilic Leukemia-Not Otherwise Specified (NOS) in the Background of a Large Cell Lymphoma. <i>Case Reports in Hematology</i> , <b>2013</b> , 2013, 458303	0.7	2
12	Implications of continued response after autologous stem cell transplantation for multiple myeloma. <i>Blood</i> , <b>2013</b> , 122, 1746-9	2.2	18

11	Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 754-754	2.2	
10	Extramedullary Leukemia Relapse In Patients With Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation: Risk Factors and Prognosis. <i>Blood</i> , <b>2013</b> , 122, 2081-2081	2.2	
9	Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. <i>Blood</i> , <b>2013</b> , 122, 1842-1842	2.2	
8	Systemic amyloidosis masquerading as iron deficiency anemia. <i>Indian Journal of Gastroenterology</i> , <b>2012</b> , 31, 351-2	1.9	
7	Granulomatous inflammation detected by endobronchial ultrasound-guided transbronchial needle aspiration in patients with a concurrent diagnosis of cancer: a clinical conundrum. <i>Journal of Bronchology and Interventional Pulmonology</i> , <b>2012</b> , 19, 176-81	1.8	8
6	Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer [A Veterans Affairs Cancer Registry analysis. <i>Journal of Geriatric Oncology</i> , <b>2011</b> , 2, 209-214	3.6	16
5	Targeted anti-cancer therapy in the elderly. <i>Critical Reviews in Oncology/Hematology</i> , <b>2011</b> , 78, 227-42	7	27
4	Effect of palliative care services on the aggressiveness of end-of-life care in the Veteran's Affairs cancer population. <i>Journal of Palliative Medicine</i> , <b>2011</b> , 14, 1231-5	2.2	66
3	Waiting in line for cancer treatments?. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2011</b> , 4, 147-9		
2	A 49-year-old woman with acute respiratory failure. <i>Chest</i> , <b>2010</b> , 138, 224-7	5.3	
1	Effects of volume and site of blood draw on blood culture results. <i>Journal of Clinical Microbiology</i> , <b>2009</b> , 47, 3482-5	9.7	71